tions in erythrocyte zinc protoporphyrin (130 Ϯ 32 vs. 72 Ϯ Erythropoietin hyporesponsiveness: From iron deficiency to 19 mol/mol heme, P Ͻ 0.05) and monthly rHuEPO dose (24.2 Ϯ iron overload. Iron deficiency is the most frequently encoun-4.5 vs. 16.8 Ϯ 3.4 ϫ 10 3 units, P Ͻ 0.05) at the end of study. tered cause of suboptimal response to recombinant human It is speculated that ascorbate supplementation not only facilierythropoietin (rHuEPO). Carefully assessing iron status is of paramount importance in chronic renal failure patients prior tates the iron release from storage sites and its delivery to to or during rHuEPO therapy. Because there is great need for hematopoietic tissues, but also increases iron utilization in eryiron in the EPO-stimulated erythroid progenitors, it is essential throid cells. Our study provides a more complete understanding that serum ferritin and transferrin saturation levels should be of the pathogenesis of iron overload-related anemia and the maintained over 300 g/liter and 30%, respectively. Investigadevelopment of an adjuvant therapy, intravenous ascorbic acid, tors have shown that oral iron is unlikely to keep pace with to the existing treatments. the iron demand for an optimal rHuEPO response in uremics. Therefore, patients with iron deficiency will always require intravenous iron therapy. The early and prompt iron supplementation can lead to reductions in rHuEPO dose and hence Renal anemia has been effectively alleviated or recost. After the iron deficiency has been corrected or excluded, versed by recombinant human erythropoietin (rHuEPO) we must remember all of the possible causes of hyporesponin the majority of end-stage renal disease (ESRD) pasiveness in every rHuEPO-treated patient. As dose requiretients [1-3]. Nowadays, most dialysis units set their target ments vary, it is not clear which dose of rHuEPO causes this hemoglobin between 10 and 12 g/dl. Achievement of this hyporesponsiveness. However, if the patient with iron repletion does not respond well after the induction period, the major target is significantly associated with an improvement in causes blunting the response to rHuEPO should be investithe quality of life, a reduction in the need for blood transgated. Most factors are reversible and remediable, except resisfusion, and an avoidance of transfusion-related sequelae tant anemia associated with hemoglobinopathy or bone mar-[2-6]. The beneficial effects of increasing hemoglobin on row fibrosis, which requires a further increase in the rHuEPO dose. By means of early detection and correction of the possible left ventricular hypertrophy [7, 8] and the correction of causes, the goal of increasing therapeutic efficacy can be malnutrition [9-11] can also reduce the morbidity and achieved. Iron overload may lead to an enhanced risk for infecmortality in dialysis patients on rHuEPO therapy. tion, cardiovascular complication, and cancer. Over-treatment
tions in erythrocyte zinc protoporphyrin (130 Ϯ 32 vs. 72 Ϯ Erythropoietin hyporesponsiveness: From iron deficiency to 19 mol/mol heme, P Ͻ 0.05) and monthly rHuEPO dose (24.2 Ϯ iron overload. Iron deficiency is the most frequently encoun-4.5 vs. 16 .8 Ϯ 3.4 ϫ 10 3 units, P Ͻ 0.05) at the end of study. tered cause of suboptimal response to recombinant human It is speculated that ascorbate supplementation not only facilierythropoietin (rHuEPO). Carefully assessing iron status is of paramount importance in chronic renal failure patients prior tates the iron release from storage sites and its delivery to to or during rHuEPO therapy. Because there is great need for hematopoietic tissues, but also increases iron utilization in eryiron in the EPO-stimulated erythroid progenitors, it is essential throid cells. Our study provides a more complete understanding that serum ferritin and transferrin saturation levels should be of the pathogenesis of iron overload-related anemia and the maintained over 300 g/liter and 30%, respectively. Investigadevelopment of an adjuvant therapy, intravenous ascorbic acid, tors have shown that oral iron is unlikely to keep pace with to the existing treatments. the iron demand for an optimal rHuEPO response in uremics. Therefore, patients with iron deficiency will always require intravenous iron therapy. The early and prompt iron supplementation can lead to reductions in rHuEPO dose and hence Renal anemia has been effectively alleviated or recost. After the iron deficiency has been corrected or excluded, versed by recombinant human erythropoietin (rHuEPO) we must remember all of the possible causes of hyporesponin the majority of end-stage renal disease (ESRD) pasiveness in every rHuEPO-treated patient. As dose requiretients [1-3]. Nowadays, most dialysis units set their target ments vary, it is not clear which dose of rHuEPO causes this hemoglobin between 10 and 12 g/dl. Achievement of this hyporesponsiveness. However, if the patient with iron repletion does not respond well after the induction period, the major target is significantly associated with an improvement in causes blunting the response to rHuEPO should be investithe quality of life, a reduction in the need for blood transgated. Most factors are reversible and remediable, except resisfusion, and an avoidance of transfusion-related sequelae tant anemia associated with hemoglobinopathy or bone mar- [2] [3] [4] [5] [6] . The beneficial effects of increasing hemoglobin on row fibrosis, which requires a further increase in the rHuEPO dose. By means of early detection and correction of the possible left ventricular hypertrophy [7, 8] and the correction of causes, the goal of increasing therapeutic efficacy can be malnutrition [9] [10] [11] can also reduce the morbidity and achieved. Iron overload may lead to an enhanced risk for infecmortality in dialysis patients on rHuEPO therapy. tion, cardiovascular complication, and cancer. Over-treatment While the efficacy of rHuEPO treatment is impressive, with iron should be avoided in dialysis patients, despite the poor responses have been documented [12] [13] [14] . Several fact that the safe upper limit of serum ferritin to avoid iron overload is not clearly defined. On the other hand, functional studies have advocated the evaluation of patients with iron deficiency may develop even when serum ferritin levels rHuEPO hyporesponsiveness [15] [16] [17] [18] [19] [20] , but the underlyare increased. Controversy remains as to whether intravenous ing mechanism is not yet fully understood. The increiron therapy can overcome this form of hyporesponsiveness in ments of effective erythropoiesis by rHuEPO are dose iron-overloaded patients. Moreover, a treatment option of iron supplementation is not warranted in these patients, as the podependent over doses ranging between 25 and 500 U/kg tential hazards of iron overload will be worsened. We demoni.v. three times a week in patients with chronic renal strated that the mean hematocrit significantly increased from failure [2, 21] . Ninety-five percent of the patients will 25 .1 Ϯ 0.9% to 31 Ϯ 1.2% after eight weeks of intravenous respond to high doses of rHuEPO, and only 5% of paascorbate therapy (300 mg three times a week) in 12 hemodialysis tients exhibit resistance to high-dose rHuEPO without patients with serum ferritin levels of more than 500 g/liter. The enhanced erythropoiesis paralleled with a rise in transferrin any obvious reasons. The response varies with doses rangsaturation (27.8 Ϯ 2.5% vs. 44.8 Ϯ 9.5%, P Ͻ 0.05) and reducing from 120 to 150 U/kg/week [2]. This variation remains obscure, and several factors could be involved. Iron deficiency is the most frequently encountered cause [22] [23] [24] , whereas other factors [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] such as infections, chronic inflammations, aluminum toxicity, secondary hyperpara- thyroidism, bone marrow dysfunction, occult blood loss, studies and discuss the issues related to (a) diagnosis and hemolysis, and hemoglobinopathy are not uncommon. treatment of iron deficiency, (b) other factors blunting Recombinant human EPO therapy is expensive and the response to rHuEPO in iron-replete state, and (c) restrained in some countries because of economic facintravenous ascorbic acid as an adjuvant therapy in irontors. The cost of rHuEPO therapy is certainly influenced overloaded patients with poor response to rHuEPO. by hyporesponsiveness to this hormone. Except refractory anemia associated with bone marrow fibrosis or hemo-IRON DEFICIENCY globinopathy, most factors leading to poor rHuEPO re-There are three components for proper erythropoiesis sponse are reversible and remediable. Based on the cost in dialysis patients: (1) rHuEPO, a stimulating factor to effectiveness, it is rational to explore the treatable factors accelerate hematopoietic activity;
(2) an adequate iron before increasing the doses when confronted with a dialreserve, a prerequisite for iron supply; and (3) an effecysis patients with rHuEPO hyporesponsiveness. By means tive iron mobilization/transport, a pivotal factor for iron of early detection and correction of the possible causes, utilization. Because adequate iron stores and iron availthe goals of reducing the rHuEPO dose and increasing ability are of great importance for the patient to get a therapeutic efficacy can be achieved. prompt response to rHuEPO, iron status should be first Sometimes the reasons for inadequate response to assessed before or during rHuEPO treatment. A number rHuEPO are not easily identified, and multiple factors of laboratory tests are useful in determining iron status may be involved. Because iron deficiency is the most in patients receiving rHuEPO (Table 1) , but an optimal common and easily treated cause, it is important to unmethod for the diagnosis of iron deficiency is still controderstand the iron metabolism in erythropoiesis and esversial. Serum ferritin is known as a noninvasive procetablish guidelines for assessment of iron status in ESRD dure, and its value is an indirect index of total body iron patients on rHuEPO treatment. In this article, we focus stores in healthy individuals [41] and patients on chronic on the issue of hyporesponsiveness to rHuEPO. The dialysis [16, 19, 20-22, 24, 42-53] . On the other hand, iron stores in ESRD patients are classified into three iron deficiency does not always mean that iron stores categories: iron deficiency, iron repletion, and iron excess. Using this classification, we present our published are diminished. The availability of iron can be reduced, a situation known as functional iron deficiency. The pa-Based on our studies [20, 24, 32, 59] and the works of others [19, 52, 53, 67, 68] , a flow chart is proposed to rameters for determining a functional iron deficiency are the transferrin saturation (TS) [2, 3, 16, 19, 20, 24, 32, evaluate iron status in dialysis patients receiving rHuEPO treatment ( Fig. 1 ). Our study showed that a serum ferri-54-59], percentage of hypochromic red cells [16, 23, 50, 58, 60, 61] , erythrocyte zinc protoporphyrin (ZPP) [62, tin level of 300 g/liter has a 100% ability to separate patients with or without initial resistance to rHuEPO 63], serum transferrin receptor [64, 65] , and erythrocyte ferritin [66] . Despite that classic methods lack sensitivity [24] . A serum ferritin level of more than 300 g/liter means that body iron stores are adequate or increased. and specificity, new methods are sophisticated and not generally available. Nowadays, serum ferritin and TS are It is essential that serum ferritin should be maintained over 300 g/liter because there is great need for iron in still the most widely accepted tests for clinical practice. the rHuEPO-stimulated erythroid progenitor cells [19, suggests that iron absorption is impaired in hemodialysis [74] or CAPD [75] patients receiving rHuEPO when 20, 24, 52, 53, 67] . A serum ferritin level of less than 100 compared with nonuremics. Moreover, gastrointestinal g/liter is defined as absolute iron deficiency [17, 21, upset, binding to phosphate binders, and noncompliance 68]. Between 100 and 300 g/liter, however, the serum may all reduce the efficacy of oral iron therapy. Investigaferritin level is not predictive of which patients respond tors also demonstrate that oral iron is unlikely keep pace to intravenous iron therapy with an improvement in with the iron demand for optimal rHuEPO response erythropoiesis [24, 32, 59] . TS is a good indicator for the [3, 55, 56, 76, 77] . Therefore, patients with absolute or current balance of supply and demand of plasma iron.
functional iron deficiency will require intensive iron sup-The calculated TS of 30% is a cut-off value for the diagplements, almost always in the form of i.v. iron. nosis of functional iron deficiency [19, 20, 52, 67] .
Intravenous iron therapy not only maintains iron In Taiwan, 82% of hemodialysis patients (N ϭ 16, 159) stores but also enhances the efficacy of rHuEPO therapy. and 66% of continuous ambulatory peritoneal dialysis Several recent studies demonstrated that the mean (CAPD) patients (N ϭ 1021) received rHuEPO treat-rHuEPO dose was reduced from 27% to 71% in patients ment in 1996 [69] . However, the average hematocrit levtreated with i.v. iron [50, 52, 59, 78-80]. For hemodialysis els in hemodialysis and CAPD patients were only 26.8% patients with overt iron deficiency, a commonly used and 26.5%, respectively. The multivariate analysis reintensive regimen is 125 or 100 mg iron by i.v. administravealed that iron deficiency, underdialysis, and inadetion for 10 consecutive treatments (Table 2) . Of interest, quate dose are the major factors of hyporesponsiveness Fishbane and Maesaka declared that the standard 1000 to rHuEPO in the Taiwanese dialysis population. Furmg dosing cycle actually may be underestimated [67] . ther analysis of the iron metabolism indices (Fig. 2) Most patients will require more than one cycle of treatshows that 51% of hemodialysis patients and 47% of ment [51, 78] . However, the potential hazard of iron CAPD patients had ferritin levels of less than 300 g/ therapy should not be disregarded. Intravenous iron liter, and 30% of hemodialysis patients and 31% of therapy is frequently linked to iron overload with the CAPD patients had TS of less than 30%. The data are increasing risks of hemosiderosis [85, 86] , hepatic or carconsistent with the finding that iron deficiency, either diac dysfunction [87] , and bacterial infection [88] . Beabsolute or functional, is the most common problem in cause the upper limit of serum ferritin or TS to avoid iron overload is not clearly defined in dialysis patients, chronic renal failure patients treated with rHuEPO.
high-dose i.v. iron therapy should be used cautiously in Iron supplementation in patients on rHuEPO therapy patients with serum ferritin of more than 100 g/liter. should be taken into account for three reasons: (a) low Giving low-dose maintenance therapy in such patients availability of dietary iron because of a restriction in is justified to in order to avoid the inadvertent hazards dietary protein and an impaired iron absorption by pre-( adequate iron stores at a dose of 450 U/kg/week i.v. or should be treated or prevented early whenever possible. This algorithm is based almost entirely on data from 300 U/kg/week subcutaneous within four to six months or failure to maintain target hemoglobin subsequently patients on hemodialysis receiving rHuEPO, whereas the same causes of hyporesponsiveness likely apply to at that dose [53] . Despite that different definitions have been proposed [14, [94] [95] [96] , this concept is accepted by patients on peritoneal dialysis or predialysis [19] . the National Kidney Foundation's Dialysis Outcome Subclinical aluminum toxicity Quality Initiative in the section on inadequate rHuEPO response [97] . Actually, the individual response is vari-
The implications of aluminum toxicity in the genesis of anemia and resistance to rHuEPO treatment have able, with doses ranging from 120 to 150 U/kg/week [2, 14, 94] . The reason for this variation in response and the been well documented. A number of proposals about aluminum-induced anemia have been made: an inhibi-mechanism for suppression of the effect of rHuEPO are still not known. In dialysis patients with iron repletion, tion of heme-synthetic enzymes [30, 100] , an interference with iron transport by competing for transferrin binding the different causes of hyporesponsiveness can be present in each patient with a different intensity [18] . These sites [101] [102] [103] , and hemolysis with increased osmotic fragility of red cells [104] . These observations are in factors include episodes of inflammations or infections [25] [26] [27] [28] [29] , aluminum toxicity [30] [31] [32] , severe hyperparathy-keeping with the recent reports of resistance to rHuEPO in aluminum-intoxicated dialysis patients [104] [105] [106] . Such roidism [33] , occult blood loss [34] , hemolysis [35] , hemoglobinopathy [36] [37] [38] [39] [40] , and folate or vitamin B 12 defi-patients characteristically exhibited microcytic anemia despite normal iron stores. Nowadays, aluminum-induced ciency [98, 99] .
It is not always easy to identify the cause of rHuEPO anemia is more often normocytic than microcytic, except in cases of severe poisoning. In iron-replete patients, hyporesponsiveness. Thus, a stepwise approach is needed to investigate patients with a poor response to rHuEPO. desferrioxamine (DFO) therapy can overcome aluminuminduced rHuEPO hyporesponsiveness, which can be de-Nissenson [19] and Tarng and Huang [20] propose an algorithm (Fig. 3) , from a clinical point of view, so that tected by serum aluminum levels pre-and post-DFO infusion [107] . Therefore, it is mandatory to monitor diagnoses may be made more concisely and conveniently and thus unnecessary examinations can be avoided. The serum aluminum levels for early diagnosis.
Our previous study showed that 39 hemodialysis pa-patients are stratified into three groups anemia by checking the mean corpuscular volume: microcytic, normo-tients of iron repletion had no aluminum-related symptoms, but the responsiveness to rHuEPO significantly cytic, and macrocytic. When the survey for folate or vitamin B 12 deficiency reveals no abnormality in macro-correlated with serum aluminum concentrations and was greater in those with lower serum aluminum levels, in-cytic anemia, iron status should be assessed in three groups. Patients with a serum ferritin of more than 300 cluding basal and 44 hours after DFO infusion [32] . Meanwhile, the post-DFO rise of serum aluminum (⌬Al) g/liter and TS of more than 30% do not suggest the presence of iron deficiency. After iron deficiency has is markedly increased and has a strong inverse correlation with mean corpuscular volume (MCV) in poor re-been corrected or excluded, further studies are needed to explore other rHuEPO-resistant causes before increasing sponders. Our data corroborates the findings that ⌬Al may be used as a means of estimating tissue stores [108] , the doses (Figs. 1 and 3) . The pathological conditions [40] . Iron deficiency ments, treatment options such as a change from hemodideveloped at the inception of or during rHuEPO therapy alysis to CAPD or renal transplantation, and from an in our patients. The early and prompt iron supplementaintravenous to subcutaneous administration route should tion can certainly promote reductions in rHuEPO dose.
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be considered for hemodialysis patients with hemoglo-Because iron deficiency is the most important factor of binopathy and high-dose rHuEPO resistance. hyporesponsiveness to rHuEPO, it might have been un-Inflammatory states and infections derdiagnosed in some of the previously reported patients with ␣or ␤-thalassemia. Despite the fact that a favorable Patients with acute or chronic inflammatory disease response was reported in our study, rHuEPO hyporefrequently present with a remarkable resistance to the sponsiveness was still noted in some thalassemic patients effects of rHuEPO. The inflammatory state may be obvion chronic dialysis [39, 110, 111] . A further increase in ous after surgery or tuberculous arthritis [25] , or indolent rHuEPO doses is usually required to achieve an optimal in perinephric abscess [26], vasculitis [27] , occult rejecresponse in these patients.
tion in a failed graft [28, 114] , and uremic pericarditis [29] . Plasma C-reactive protein (CRP) is a useful marker Hemoglobinopathies and chronic hemolysis for confirming and quantitating the severity of inflam-Besides thalassemia, sickle cell exhibits an additional mation in patients undergoing dialysis [28, 29, 115, 116] . cause for anemia in patients with chronic renal failure An increase in plasma CRP probably best reflects the disease [36, 112, 113] . We reported a hemodialysis painflammatory state or infections in dialysis patients. tient with rHuEPO resistance and hemoglobinopathy Therefore, it is prudent to determine plasma CRP to rule J-Meinung [37] , which was initially found by hemoglobin out the presence of an underlying inflammation in patients electrophoresis and finally proven by molecular genetic of unexplained poor responses to rHuEPO (Fig. 3) . Early analysis. Our patient had splenomegaly, an increased detection and prompt management, if possible, can reserum bilirubin and reticulocyte index, and a reduced store the responsiveness to rHuEPO and reduce the dose haptoglobin level, which are hallmarks of chronic active requirements [27] [28] [29] . hemolysis. As the major cause of anemia is hemolysis in patients of hemoglobinopathy and ESRD, rHuEPO in IRON OVERLOAD the usual doses may not be effective in correcting anemia.
Iron excess in dialysis patients may be represented by Larger doses are required for an optimal response in these individuals; however, the treatment cost is more a serum ferritin level of more than 500 g/liter as pro- , more than 800 g/ els of more than 500 g/liter may have functional iron deficiency and respond to i.v. iron therapy [52, 91, 118] , liter as found by Macdougall et al [118] , or more than 1000 g/liter as proposed by Eschbach et al [119] . Iron but this beneficial effect was not observed by Rosenlö f et al [83] and our preliminary study (unpublished data). overload not only increases the cardiovascular and infectious morbidity in dialysis patients but sometimes may Even i.v. iron therapy can circumvent this resistance; iron supplementation could worsen hemosiderosis in iron-cause relative resistance to rHuEPO. El-Reshaid et al showed that the rHuEPO dose in the maintenance phase overloaded patients. El-Reshaid et al declared that iron supplementation is not warranted in these patients [120] . is nearly twice as large in iron-overloaded patients (ferritin more than 1100 g/liter) as in controls (ferritin 100
The risks related to iron overload do not justify this treatment option. In fact, rHuEPO is an effective treat-to 600 g/liter) [120] . Interestingly, TS decreased to a level of less than 30% in six of 11 iron-overloaded pa-ment for iron overload. It is rational to increase the dose by an escalation method in these patients if other factors tients at the end of their study. The mechanism of this form of rHuEPO hyporesponsiveness is not yet fully pertaining to inadequate rHuEPO response do not exist. However, this should be balanced by the cost of high-understood, but inadequate iron mobilization and defective iron utilization are the possible reasons. Ali et al dose rHuEPO therapy. Therefore, an adjuvant therapy is needed not only to improve the rHuEPO response disclosed that 10 hemodialysis patients with a mean ferritin level of 1336 g/liter have depleted marrow iron but also to avoid the inadvertent hazard. It has been demonstrated that rHuEPO resistance due stores [85] . Figure 1 also shows that a serum ferritin level of more than 300 g/liter does not exclude functional to functional iron deficiency in four hemodialysis patients with iron overload (ferritin of more than 500 g/ iron deficiency.
Several studies reported that patients with ferritin lev-liter) can be overcome by i.v. ascorbic acid therapy (500
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mg, one to three times per week) in a preliminary study patients with an inadequate response ( Figs. 1 and 3) . Further research is needed to resolve the following prob- [121] . To elucidate the possible mechanisms further, 24 hemodialysis patients with serum ferritin levels of more lems: (a) the optimal diagnostic testing for iron deficiency, (b) the upper limit of serum ferritin or TS to than 500 g/liter were enrolled in our study [122] . Twelve patients failed to achieve the target hematocrit level of avoid iron overload during i.v. iron therapy, and (c) the adjuvant therapy other than iron supplementation for 30% in spite of a rHuEPO dose of more than 150 U/kg/ week. Ascorbic acid (300 mg) is administered intrave-rHuEPO in hemodialysis patients with iron overload. nously postdialysis three times per week for eight weeks to all 12 patients. Another 12 patients treated with ACKNOWLEDGMENTS rHuEPO dose of less than 150 U/kg/week could maintain significantly lower, and basal erythrocyte ZPP and the rHuEPO dose were higher than in the controls (Table 3) . crit significantly increased with a parallel rise in TS and E-mail: dctarng@vghtpe.gov.tw a decrease in ZPP in the study group (Fig. 4) . Meanwhile, the rHuEPO dose was also significantly reduced at the REFERENCES end of study. In contrast, the parameters mentioned ear- [34] [35] [36] [37] [38] [39] 1990 and to exclude other remediable factors in iron-replete
